Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 588,330
  • Shares Outstanding, K 76,110
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,870 K
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.14
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.20
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.33 +45.03%
on 01/27/20
9.25 -16.46%
on 02/20/20
+1.73 (+28.83%)
since 01/24/20
3-Month
2.43 +218.11%
on 12/02/19
9.25 -16.46%
on 02/20/20
+4.98 (+181.09%)
since 11/26/19
52-Week
1.57 +392.36%
on 03/06/19
9.25 -16.46%
on 02/20/20
+5.85 (+311.17%)
since 02/26/19

Most Recent Stories

More News
Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results...

APTO : 7.73 (-0.39%)
Are Options Traders Betting on a Big Move in Aptose (APTO) Stock?

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

APTO : 7.73 (-0.39%)
Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company...

APTO : 7.73 (-0.39%)
Is the Options Market Predicting a Spike in Aptose (APTO) Stock?

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

APTO : 7.73 (-0.39%)
Aptose Biosciences to Present at Biotech Showcase(TM) 2020 Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G....

APTO : 7.73 (-0.39%)
Aptose Announces Closing of Public Offering of Common Shares

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the "Offering")...

APTO : 7.73 (-0.39%)
Aptose Announces Pricing of Public Offering of Common Shares

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the "Offering")...

APTO : 7.73 (-0.39%)
Aptose Announces Proposed Public Offering of Common Shares

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its common shares (the "Offering"). In addition, Aptose...

APTO : 7.73 (-0.39%)
Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019

Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat...

CNSP : 3.79 (-5.01%)
CLVS : 7.48 (-6.38%)
ARQL : 20.00 (+0.15%)
APTO : 7.73 (-0.39%)
APS.TO : 10.25 (-0.49%)
FATE : 31.88 (+4.97%)
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the presentation...

APTO : 7.73 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade APTO with:

Business Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in...

See More

Key Turning Points

2nd Resistance Point 8.39
1st Resistance Point 8.06
Last Price 7.73
1st Support Level 7.48
2nd Support Level 7.23

See More

52-Week High 9.25
Last Price 7.73
Fibonacci 61.8% 6.32
Fibonacci 50% 5.41
Fibonacci 38.2% 4.50
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar